Abstract
Objectives
The relative efficacy and safety of tofacitinib and baricitinib were assessed in patients with rheumatoid arthritis (RA) with an inadequate response to disease-modifying anti-rheumatic drugs (DMARDs) or biologics.
Methods
We performed a Bayesian network meta-analysis to combine direct and indirect evidence from randomized controlled trials (RCTs) to examine the efficacy and safety of tofacitinib and baricitinib in combination with DMARDs in RA patients with an inadequate DMARD or biologic response.
Results
Twelve RCTs including 5883 patients met the inclusion criteria. There were 15 pairwise comparisons including 10 direct comparisons of 6 interventions. Tofacitinib 10 mg + methotrexate (MTX) and baricitinib 4 mg + MTX were among the most effective treatments for active RA with an inadequate DMARD or biologic response, followed by baricitinib 2 mg + MTX, tofacitinib 5 mg + MTX, and adalimumab + MTX. The ranking probability based on the surface under the cumulative ranking curve (SUCRA) indicated that tofacitinib 10 mg + MTX had the highest probability of being the best treatment to achieve the ACR20 response rate (SUCRA = 0.865), followed by baricitinib 4 mg + MTX (SUCRA = 0.774), baricitinib 2 mg + MTX (SUCRA = 0.552), tofacitinib 5 mg + MTX (SUCRA = 0.512), adalimumab + MTX (SUCRA = 0.297), and placebo + MTX (SUCRA <0.001). No significant differences were observed in the incidence of serious adverse events after treatment with tofacitinib + MTX, baricitinib + MTX, adalimumab + MTX, or placebo + MTX.
Conclusions
In RA patients with an inadequate response to DMARDs or biologics, tofacitinib 10 mg + MTX and baricitinib 4 mg + MTX were the most efficacious interventions and were not associated with a significant risk of serious adverse events.
Zusammenfassung
Ziel
Bei Patienten mit rheumatoider Arthritis (RA) und unzureichendem Ansprechen auf krankheitsmodifizierende Medikamente („disease-modifying anti-rheumatic drugs“, DMARD) oder Biologika wurden die relative Wirksamkeit und Sicherheit von Tofacitinib und Baricitinib ermittelt.
Methoden
Die Autoren führten eine Bayes-Netz-Metaanalyse zur Kombination direkter und indirekter Evidenz aus randomisierten kontrollierten Studien („randomized controlled trials“, RCT) durch, die der Untersuchung der Wirksamkeit und Sicherheit von Tofacitinib und Baricitinib zusätzlich zu DMARD bei RA-Patienten mit unzureichendem Ansprechen auf DMARD oder Biologika diente.
Ergebnisse
Die Einschlusskriterien erfüllten 12 RCT mit 5883 Patienten. Es wurden 15 paarweise erfolgende Vergleiche einschließlich 10 direkter Vergleiche von 6 Interventionen durchgeführt. Tofacitinib 10 mg + Methotrexat (MTX) und Baricitinib 4 mg + MTX gehörten zu den wirksamsten Therapien bei aktiver RA mit unzureichendem Ansprechen auf DMARD oder Biologika, nächstwirksam waren Baricitinib 2 mg + MTX, Tofacitinib 5 mg + MTX und Adalimumab + MTX. Die auf dem SUCRA-Wert („surface under the cumulative ranking curve“) basierende Rangfolgewahrscheinlichkeit ergab für Tofacitinib 10 mg + MTX die größte Wahrscheinlichkeit, die beste Behandlung zur Erzielung einer Ansprechrate mit 20%iger Linderung der Symptome (ACR20) zu sein (SUCRA = 0,865); es folgten Baricitinib 4 mg + MTX (SUCRA = 0,774), Baricitinib 2 mg + MTX (SUCRA = 0,552), Tofacitinib 5 mg + MTX (SUCRA = 0,512), Adalimumab + MTX (SUCRA = 0,297) und Placebo + MTX (SUCRA <0,001). Bei der Inzidenz schwerer unerwünschter Ereignisse nach Behandlung mit Tofacitinib + MTX, Baricitinib + MTX, Adalimumab + MTX oder Placebo + MTX wurden keine signifikanten Unterschiede festgestellt.
Schlussfolgerung
Bei RA-Patienten mit unzureichendem Ansprechen auf DMARD oder Biologika stellten Tofacitinib 10 mg + MTX und Baricitinib 4 mg + MTX die wirksamsten Interventionen dar, sie waren dabei nicht mit einem signifikanten Risiko für schwere unerwünschte Ereignisse verbunden.
Similar content being viewed by others
References
Aletaha D, Landewe R, Karonitsch T et al (2008) Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Care Res 59(10):1371–1377
Brown S, Hutton B, Clifford T et al (2014) A Microsoft-Excel-based tool for running and critically appraising network meta-analyses—an overview and application of NetMetaXL. Syst Rev 3(1):110
Burmester GR, Benda B, Gruben D et al (2013) Tofacitinib for rheumatoid arthritis—Authors’ reply. Lancet 381(9880):1812–1813
Caldwell DM, Ades A, Higgins J (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331(7521):897
Catalá-López F, Tobías A, Cameron C et al (2014) Network meta-analysis for comparing treatment effects of multiple interventions: an introduction. Rheumatol Int 34(11):1489–1496
Changelian PS, Flanagan ME, Ball DJ et al (2003) Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302(5646):875–878
Chrencik JE, Patny A, Leung IK et al (2010) Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. J Mol Biol 400(3):413–433
Dias S, Welton NJ, Sutton AJ et al (2013) Evidence synthesis for decision making 4 inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making 33(5):641–656
Dougados M, van der Heijde D, Chen Y‑C et al (2015) LB0001 Baricitinib, an oral Janus Kinase (JAK) 1/JAK2 inhibitor, in patients with active Rheumatoid Arthritis (RA) and an inadequate response to CDMARD therapy: results of the phase 3 RA-build study. Ann Rheum Dis 74(Suppl 2):79–79
Fleischmann R, Cutolo M, Genovese MC et al (2012) Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 64(3):617–629
Fleischmann R, Kremer J, Cush J et al (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367(6):495–507
Fleischmann R, Takeuchi T, Schlichting DE et al (2015) Baricitinib, methotrexate, or baricitinib plus methotrexate in patients with early rheumatoid arthritis who had received limited or no treatment with disease-modifying anti-rheumatic drugs (DMARDs): phase 3 trial results. In: Arthritis & Rheumatology. Wiley-Blackwell, Hoboken
Genovese MC, Kremer J, Zamani O et al (2016) Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 374(13):1243–1252
Ghoreschi K, Laurence A, O’Shea JJ (2009) Janus kinases in immune cell signaling. Immunol Rev 228(1):273–287
Ghoreschi K, Laurence A, O’Shea JJ (2009) Janus kinases in immune cell signaling. Immunol Rev 228(1):273–287
Greenwald M, Fidelus-Gort R, Levy R et al (2010) A randomized dose-ranging, placebo-controlled study of INCB028050, a selective JAK1 and JAK2 inhibitor in subjects with active rheumatoid arthritis. Arthritis Rheum 62(Suppl 10):2172
Higgins J, Jackson D, Barrett J et al (2012) Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 3(2):98–110
Hochberg MC, Chang RW, Dwosh I et al (1992) The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 35(5):498–502
Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1–12
Keystone EC, Taylor PC, Drescher E et al (2015) Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis 74(2):333–340
Kremer J, Li ZG, Hall S et al (2013) Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 159(4):253–261
Kremer JM, Bloom BJ, Breedveld FC et al (2009) The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 60(7):1895–1905
Kremer JM, Cohen S, Wilkinson BE et al (2012) A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 64(4):970–981
Kubo S, Yamaoka K, Kondo M et al (2013) The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann Rheum Dis 73:2192–2198
Lee EB, Fleischmann R, Hall S et al (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370(25):2377–2386
Lee Y‑H, Bae S‑C, Song G‑G (2012) Omega-3 polyunsaturated fatty acids and the treatment of rheumatoid arthritis: a meta-analysis. Arch Med Res 43(5):356–362
Lee Y, Bae S‑C (2018) Comparative efficacy and safety of baricitinib 2 mg and 4 mg in patients with active rheumatoid arthritis. Z Rheumatol 77(4):335–342
Lee Y, Bae S, Song G (2013) Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy
Lee YH, Bae S‑C, Song GG (2015) Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Rheumatol Int 35(12):1965–1974
Meyer DM, Jesson MI, Li X et al (2010) Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 7:41
Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264–269
Norman P (2014) Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs 23(8):1067–1077
Park Y‑W, Kim K‑J, Yang H‑I et al (2017) Comparing effectiveness rituximab (Mabthera®) to other second-line biologics for rheumatoid arthritis treatment in patients refractory to or intolerant of first-line anti-tumor necrosis factor agent: an observational study. J Rheum Dis 24(4):227–235
Roskoski R Jr. (2016) Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacol Res 111:784–803
Salanti G, Ades A, Ioannidis JP (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64(2):163–171
Schindler C, Levy DE, Decker T (2007) JAK-STAT signaling: from interferons to cytokines. J Biol Chem 282(28):20059–20063
Shi JG, Chen X, Lee F et al (2014) The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J Clin Pharmacol 54(12):1354–1361
Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388(10055):2023–2038. https://doi.org/10.1016/S0140-6736(16)30173-8
Tanaka Y, Emoto K, Cai Z et al (2016) Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled study. J Rheumatol 43(3):504–511
Tanaka Y, Suzuki M, Nakamura H et al (2011) Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res 63(8):1150–1158
Taylor PC, Keystone EC, Van Der Heijde D et al (2015) Baricitinib versus placebo or adalimumab in patients with active rheumatoid arthritis (RA) and an inadequate response to background methotrexate therapy: results of a phase 3 study. In: Arthritis & rheuamtology. Wiley-Blackwell, Hoboken
Traynor K (2012) FDA approves tofacitinib for rheumatoid arthritis. Am J Health Syst Pharm 69(24):2120
Valkenhoef G, Lu G, Brock B et al (2012) Automating network meta-analysis. Res Synth Methods 3(4):285–299
van der Heijde D, Tanaka Y, Fleischmann R et al (2013) Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65(3):559–570
van Vollenhoven RF, Fleischmann R, Cohen S et al (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367(6):508–519
Acknowledgements
This study was supported in part by a grant of the Korea Healthcare technology R&D Project, Ministry for Health and Welfare, Republic of Korea (HI15C2958).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
S.-C. Bae and Y. H. Lee have no financial or non-financial conflict of interest to declare.
This article does not contain any studies with human participants or animals performed by any of the authors.
Additional information
Redaktion
U. Müller-Ladner, Bad Nauheim
U. Lange, Bad Nauheim
Rights and permissions
About this article
Cite this article
Bae, SC., Lee, Y.H. Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Z Rheumatol 78, 559–567 (2019). https://doi.org/10.1007/s00393-018-0531-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00393-018-0531-5